All Episodes

Serotonin Synthesis Amplification to Augment the Therapeutic Efficacy of Serotonin Reuptake Inhibitor Antidepressants: Five Decades of Clinical Evidence

Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?

Current Clinical Psychopharmacology Integrated Practice: The Crisis in Teaching and Its Effects on Quality of Care

The Use of VMAT2 Inhibitors for Tardive Dyskinesia

Reduction of Loss of Control Eating in Youth With Attention-Deficit/Hyperactivity Disorder Following Initiation of Stimulant Medication: A Prospective Study

Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study

Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis

Diet Drug Interactions: Achieving and Maintaining Ketosis As Adjunct to Psychotropic Polypharmacotherapy

Anticholinergic Equivalence in Psychotropic Medications: A Guide for Psychiatrists

Fact Versus Fear: Antidepressants in Children and Adolescents

How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression?

Variability in Response to Antidepressants

A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders

How Does Drug Company Marketing Affect Physician Prescribing?

A Call for Updates to Clozapine's Product Label

Practical Strategies for Prescribing Clozapine

At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy)

Clinical Management of Designer Benzodiazepine Intoxication: A Systematic Review

Growing Concerns Over Valproate Teratogenicity Present an Opportunity for Lithium

Ethics in Psychedelic Science: Promises and Responsibilities

Broad-Spectrum Micronutrients or Antidepressants for Antenatal Depression: Effect on Maternal and Infant Birth Outcomes in an Observational Secondary Analysis of NUTRIMUM

Psychopharmacologic Laziness

Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States

Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty

Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges

High-dose propranolol for severe and chronic aggression in autism spectrum disorder

Prebiotic Treatment in People With Schizophrenia

Challenges in the Treatment of Psychotic Bipolar Depression

Floxing and Clinical Psychopharmacology

A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Clinical Presentations of Bupropion Prescription Drug Misuse: A Systematic Review

The Role of Case Series and Case Reports in Evidence-Based Medicine

Current Status and Treatment of Rapid Cycling Bipolar Disorder

GLP-1 Weight Loss Drugs in Patients With Bipolar Disorder or Eating Disorders

Celebrating 70 Years of the First Publication on Antipsychotic Treatment in North America by Heinz E. Lehmann and Gorman E. Hanrahan: Would Their Methodology Still Be Conceivable?

Direct-to-Consumer Advertising Survey of Psychiatrists in Massachusetts and Michigan

The Need for Examining the Role of Psychostimulants in Treatment of Methamphetamine Use/Dependence

Assessing Adherence to Clozapine: Practical Considerations

Artificial Intelligence and the Journal of Clinical Psychopharmacology

Adherence to Psychotropic Medication Before and During COVID-19: A Population-Wide Retrospective Observational Study

A System for Rapidly Yet Rigorously Evaluating the Quality of Randomized Controlled Trials

Valproic Acid–Associated Hyperammonemia: A Systematic Review

Anosognosia and Psychosis: More Research is Needed on How Best to Treat People Unaware of Their Disorder

κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine

Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia

Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy

Endoxifen Approval for Bipolar Disorder in India: A Premature or a Pragmatic Decision?

Psychedelics in the Treatment of Depression: A Critical Appraisal of Evidence

The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward

Effects of Selective Serotonin Reuptake Inhibitor Use on MDMA–Assisted Therapy for Posttraumatic Stress Disorder

Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity

Panic Disorder Seeks More Specific Drugs for Treatment : Might the Amygdala Be the Best Target?

Unfair Criticisms of Psychopharmacology

Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series

Should Antipsychotic Medications Be Prescribed to Patients with Nonpsychotic Depression?

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents

Calcium Channel Antagonists for Mood Disorders

Structured Interventions to Optimize Polypharmacy in Psychiatric Treatment and Nursing Homes: A Systematic Review

Raising the Quality of Psychopharmacology Care

Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs

Are the same medications that are used in the acute treatment of depression the most suitable for preventing relapse?

Lifetime cannabis use disorder is not associated with lifetime impulsive behavior and severe violence in patients with schizophrenia spectrum disorders from a high-security hospital

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior

The Placenta and Psychiatry?

Time to reconsider monoamine oxidase inhibitors (MAOIs) for Obsessive Compulsive Disorder? A case series using phenelzine

Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness

Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?

Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers

The Pitfalls of Psychotropic Polypharmacy